Related Experiment Video
Updated: May 16, 2026
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
How We Approach Intraocular Retinoblastoma in 2026: Agreement and Disagreement in Four Referral Centers in the USA
David H Abramson1, Carol L Shields2, Francis L Munier3
1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abstract:
Retinoblastoma management has changed notably in the past 11 years. Here, four retinoblastoma experts in the USA and Europe report their management recommendations. Retinoblastoma is now the most curable of all pediatric cancers in developed countries, and major clinical trials are scarce; thus, the experience of these centers carries important information for clinicians worldwide. There is increasing use of intra-arterial chemotherapy for unilateral and bilateral disease in naïve and recurrent eyes. Intravitreal chemotherapy is increasingly being used, and high-dose topotecan for vitreous seeds, anterior chamber tumor (combined with intracameral injection), and recurrent retinal and subretinal tumors is becoming the standard approach.
Insights
Retinoblastoma management has evolved, with experts recommending increased use of intra-arterial and intravitreal chemotherapy. High-dose topotecan is now standard for various retinoblastoma tumors, improving pediatric cancer cure rates.
Area of Science:
- Ophthalmology
- Pediatric Oncology
- Cancer Treatment
Background:
- Retinoblastoma management has seen significant changes over the last decade.
- Expert recommendations from leading US and European centers offer valuable insights due to scarce clinical trials.
- Retinoblastoma is highly curable in developed nations, emphasizing the importance of experienced center data.
